Research
The National Institute of Allergy and Infectious Diseases (NIAID) supports research to develop improved treatments and vaccines for hepatitis A.
NIAID scientists have developed several candidate vaccines against hepatitis A virus (HAV) in collaboration with the pharmaceutical company GlaxoSmithKline (GSK). One such candidate was modified and became the currently licensed GSK inactivated hepatitis A vaccine.
To improve their understanding of how HAV causes disease,
NIAID-supported scientists are examining the role of human genes in HAV infection and studying how the immune system fights HAV infection